Cabozantinib for Advanced Urothelial Cancer

Part of paid clinical trials in Bethesda, Maryland.

Sponsor: National Cancer Institute (NCI)
Study ID: NCT01688999
Phase: PHASE2
Status: Completed

Conditions

Kidney Neoplasms
Urethral Neoplasms
Urinary Bladder Neoplasms
Urothelial Carcinoma

Eligibility Criteria

Sex: ALL
Age: 18 Years - 99 Years
Healthy Volunteers: Not accepted

Interventions

Cabozantinib — DRUG
60 mg by mouth (PO) daily each 28 day cycle. Treatment continues until toxicity or disease progression.

Study Details

Background: \- Cabozantinib is a drug that slows the growth of blood vessels that feed tumors. It is approved for medullary thyroid cancer. However, studies have shown that prostate and ovarian tumors respond to it. Researchers want see if cabozantinib can be a safe and effective treatment for urothelial cancer. Objectives: \- To test the safety and effectiveness of cabozantinib for advanced urothelial cancer. Eligibility: \- Individuals at least 18 years of age who have advanced urothelial cancer that has not responded to standard treatments. Design: * Participants will be screened with a physical exam and medical history. Blood and urine samples will be collected. Tumor tissue samples will also be collected. Imaging studies will also be performed. * Participants will take cabozantinib by mouth once per day on each day of a 28-day cycle. * Treatment will be monitored with frequent blood tests and imaging studies. * Participants will continue to take the study drug for as long as their cancer does not worsen and side effects are not too severe.